Laboratorios Farmaceuticos Rovi, S.A. (BME: ROVI)

ROVI Statistics

Total Valuation

Laboratorios Farmaceuticos Rovi has a market cap or net worth of EUR 3.71 billion. The enterprise value is 3.79 billion.

Market Cap	3.71B
Enterprise Value	3.79B

Important Dates

The next estimated earnings date is Thursday, November 7, 2024.

Earnings Date	Nov 7, 2024
Ex-Dividend Date	Jul 8, 2024

Share Statistics

Laboratorios Farmaceuticos Rovi has 51.15 million shares outstanding. The number of shares has decreased by -2.19% in one year.

Shares Outstanding	51.15M
Shares Change (YoY)	-2.19%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	22.29%
Float	18.61M

Valuation Ratios

The trailing PE ratio is 25.55 and the forward PE ratio is 20.39. Laboratorios Farmaceuticos Rovi's PEG ratio is 1.36.

PE Ratio	25.55
Forward PE	20.39
PS Ratio	4.86
PB Ratio	8.13
P/FCF Ratio	101.22
PEG Ratio	1.36

Enterprise Valuation

The stock's EV/EBITDA ratio is 17.59, with an EV/FCF ratio of 103.48.

EV / Earnings	25.61
EV / Sales	4.87
EV / EBITDA	17.59
EV / EBIT	19.89
EV / FCF	103.48

Financial Position

The company has a current ratio of 1.98, with a Debt / Equity ratio of 0.25.

Current Ratio	1.98
Quick Ratio	0.66
Debt / Equity	0.25
Debt / EBITDA	0.56
Debt / FCF	3.31
Interest Coverage	101.17

Financial Efficiency

Return on equity (ROE) is 29.52% and return on invested capital (ROIC) is 20.03%.

Return on Equity (ROE)	29.52%
Return on Assets (ROA)	13.57%
Return on Capital (ROIC)	20.03%
Revenue Per Employee	364,062
Profits Per Employee	69,272
Employee Count	2,111
Asset Turnover	0.89
Inventory Turnover	0.89

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +37.68% in the last 52 weeks. The beta is 0.51, so Laboratorios Farmaceuticos Rovi's price volatility has been lower than the market average.

Beta (5Y)	0.51
52-Week Price Change	+37.68%
50-Day Moving Average	76.35
200-Day Moving Average	77.65
Relative Strength Index (RSI)	41.19
Average Volume (20 Days)	108,482

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Laboratorios Farmaceuticos Rovi had revenue of EUR 778.00 million and earned 148.03 million in profits. Earnings per share was 2.84.

Revenue	778.00M
Gross Profit	461.87M
Operating Income	190.71M
Pretax Income	190.72M
Net Income	148.03M
EBITDA	210.21M
EBIT	190.71M
Earnings Per Share (EPS)	2.84

Balance Sheet

The company has 45.12 million in cash and 121.16 million in debt, giving a net cash position of -76.04 million or -1.49 per share.

Cash & Cash Equivalents	45.12M
Total Debt	121.16M
Net Cash	-76.04M
Net Cash Per Share	-1.49
Equity (Book Value)	482.76M
Book Value Per Share	8.92
Working Capital	268.33M

Cash Flow

In the last 12 months, operating cash flow was 90.46 million and capital expenditures -53.82 million, giving a free cash flow of 36.64 million.

Operating Cash Flow	90.46M
Capital Expenditures	-53.82M
Free Cash Flow	36.64M
FCF Per Share	0.72

Margins

Gross margin is 59.37%, with operating and profit margins of 24.51% and 19.03%.

Gross Margin	59.37%
Operating Margin	24.51%
Pretax Margin	24.51%
Profit Margin	19.03%
EBITDA Margin	27.02%
EBIT Margin	24.51%
FCF Margin	4.71%

Dividends & Yields

This stock pays an annual dividend of 1.10, which amounts to a dividend yield of 1.52%.

Dividend Per Share	1.10
Dividend Yield	1.52%
Dividend Growth (YoY)	-14.69%
Years of Dividend Growth	4
Payout Ratio	46.64%
Buyback Yield	2.19%
Shareholder Yield	3.71%
Earnings Yield	3.91%
FCF Yield	0.99%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Laboratorios Farmaceuticos Rovi has an Altman Z-Score of 8.27.

Altman Z-Score	8.27
Piotroski F-Score	n/a